Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
In May 2016, countries using oral polio vaccine for routine immunization switched from trivalent oral poliovirus vaccine (tOPV) to bivalent type 1 and 3 OPV (bOPV). This was done in order to reduce risks from type 2 vaccine-derived polioviruses (VDPV2) and vaccine-associated paralytic poliomyelitis (VAPP) and to introduce ≥1 dose of inactivated poliovirus vaccine (IPV) to mitigate post-switch loss of type 2 immunity. We conducted a literature review of studies that assessed humoral and intestinal immunogenicity induced by the newly recommended schedules. Differences in seroconversion rates were closely associated with both timing of first IPV administration and number of doses administered. All studies demonstrated high levels of immunity for types 1 and 3 regardless of immunization schedule. When administered late in the primary series, a second dose of IPV closed the humoral immunity gap against polio type 2 associated with a single dose. IPV doses and administration schedules appear to have limited impact on type 2 excretion following challenge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polio vaccination: Past, present and future
Bandyopadhyay, A. S., Garon, J., Seib, K., & Orenstein, W. A. (2015) · Future Microbiology · doi:10.2217/fmb.15.19 · Cited by 276 · cited 2×
“As the last naturally occurring WPV2 was isolated in 1999 and approximately 90 of all cVDPV outbreaks since 2000 have been attributed to type 2 viruses [2], a globally coordinated “switch” from trivalent OPV (tOPV) to bivalent type 1 and 3 OPV (bOPV) occurred in April 2016– May 2016, resulting in cessation of all use…”
BackgroundSelf-citationHampton, L. M., Farrell, M., Ramirez-Gonzalez, A., Menning, L., Shendale, S., Lewis, I., Rubin, J., Garon, J., Harris, J., Hyde, T., et al. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6535a3 · Cited by 193
Efficacy of inactivated poliovirus vaccine in India
Jafari, H., Deshpande, J. M., Sutter, R. W., Bahl, S., Verma, H., Ahmad, M., Kunwar, A., Vishwakarma, R., Agarwal, A., Jain, S., et al. (2014) · Science · doi:10.1126/science.1255006 · Cited by 112
Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa054960 · Cited by 90
Cited by
Van Damme, P., De Coster, I., Bandyopadhyay, A. S., Revets, H., Withanage, K., De Smedt, P., Suykens, L., Oberste, M. S., Weldon, W. C., Costa-Clemens, S. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31279-6 · Cited by 141
Self-citationZaman, K., Bandyopadhyay, A. S., Hoque, M., Gast, C., Yunus, M., Jamil, K. M., Mainou, B. A., Konopka-Anstadt, J. L., Hendley, W. S., Vincent, A., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02397-2 · Cited by 39
Self-citationThe role of genetic sequencing and analysis in the polio eradication programme
Jorgensen, D., Pons-Salort, M., Shaw, A. G., & Grassly, N. C. (2020) · Virus Evolution · doi:10.1093/ve/veaa040 · Cited by 31
Mirzoev, A., Macklin, G. R., Zhang, Y., Mainou, B. A., Sadykova, U., Olsavszky, V. S., Huseynov, S., Ruziev, M., Saidzoda, F., Bobokhonova, M., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00412-0 · Cited by 30
Metadata
- Authors
- Bandyopadhyay, A. S., Modlin, J. F., Wenger, J., & Gast, C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-10-30
- Volume
- 67
- Issue
- suppl_1
- Pages
- S35-S41
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2899259430
- Cited by
- 31
- References
- 4
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.